An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape
- DOI
- 10.1186/s12943-026-02686-7
- Published
- 2026-05-13
- Container
- Molecular Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12943-026-02686-7,
title = {An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape},
author = {Yanlun Gu and Bingqi Dong and Xia Teng and Lin Chen and Yang Yang and Xiaojiao Sun and Song Song and Binzhi Qian and Yufang Sun and Jixin Zhang and Zhigang Zheng and Yuke Chen and Yimin Cui and Zhuona Rong and Xiaocong Pang},
year = {2026},
journal = {Molecular Cancer},
doi = {10.1186/s12943-026-02686-7},
url = {https://doi.org/10.1186/s12943-026-02686-7}
}RIS
TY - JOUR TI - An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape AU - Yanlun Gu AU - Bingqi Dong AU - Xia Teng AU - Lin Chen AU - Yang Yang AU - Xiaojiao Sun AU - Song Song AU - Binzhi Qian AU - Yufang Sun AU - Jixin Zhang AU - Zhigang Zheng AU - Yuke Chen AU - Yimin Cui AU - Zhuona Rong AU - Xiaocong Pang PY - 2026 JO - Molecular Cancer DO - 10.1186/s12943-026-02686-7 UR - https://doi.org/10.1186/s12943-026-02686-7 ER -
APA
Gu, Y., Dong, B., Teng, X., Chen, L., Yang, Y., Sun, X., Song, S., Qian, B., Sun, Y., Zhang, J., Zheng, Z., Chen, Y., Cui, Y., Rong, Z., & Pang, X. (2026). An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape. Molecular Cancer. https://doi.org/10.1186/s12943-026-02686-7
Source records
- crossref · retrieved 2026-09-25T16:28:52.394Z